FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.
What happened
FDA reviewed the website www.nomida.biz and found it offered semaglutide and tirzepatide products and kits for weight loss. FDA said these are unapproved new drugs because no approved applications are in effect for the products offered, and they are misbranded because their labeling lacks adequate directions for use and they are offered without a prescription. FDA also noted the products are intended for injection, which it said heightens public health concern.
What FDA found
The website offered semaglutide and tirzepatide as new drugs without FDA-approved applications.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]The drug labeling did not include adequate directions for a layperson to use the products safely.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]The website offered prescription drugs without requiring a prescription.
FD&C Act §§ 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]By offering the drugs for sale to U.S. consumers, the website caused misbranded drugs to enter interstate commerce.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Nomida.biz to cease offering any unapproved and misbranded drugs for sale to U.S. consumers. It asks for a written response within 15 working days describing corrective steps and how recurrence will be prevented, or an explanation and timeline if corrections cannot be completed in that time.
Who should pay attention
- consumers buying weight-loss drugs online
- online sellers of GLP-1 products
- clinics and telehealth companies that point patients to product websites
This is a summary. Read the original letter on fda.gov.